{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:42Z","timestamp":1792783122260,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"GT Medical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11060-023-04545-7","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T03:01:41Z","timestamp":1706410901000},"page":"441-450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["GammaTile\u00ae (GT) as a brachytherapy platform for rapidly proliferating glioblastomas: from case series to clinical trials"],"prefix":"10.1007","volume":"166","author":[{"given":"Anudeep","family":"Yekula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic J.","family":"Gessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Dusenbery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"key":"4545_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/now207","volume":"18","author":"QT Ostrom","year":"2016","unstructured":"Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009\u20132013. Neuro Oncol 18:v1\u2013v75","journal-title":"Neuro Oncol"},{"key":"4545_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"4545_CR3","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","volume":"310","author":"A Omuro","year":"2013","unstructured":"Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA 310:1842\u20131850","journal-title":"JAMA"},{"key":"4545_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","volume":"28","author":"SJ Bagley","year":"2022","unstructured":"Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E et al (2022) Glioblastoma clinical trials: current landscape and opportunities for improvement. Clin Cancer Res 28:594\u2013602","journal-title":"Clin Cancer Res"},{"key":"4545_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/neuonc\/nov029","volume":"17","author":"AL Stensj\u00f8en","year":"2015","unstructured":"Stensj\u00f8en AL, Solheim O, Kvistad KA, H\u00e5berg AK, Salvesen \u00d8, Berntsen EM (2015) Growth dynamics of untreated glioblastomas in vivo. Neuro Oncol 17:1402\u20131411","journal-title":"Neuro Oncol"},{"key":"4545_CR6","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","volume":"20","author":"ME Davis","year":"2016","unstructured":"Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 20:S2-8","journal-title":"Clin J Oncol Nurs"},{"key":"4545_CR7","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.21037\/tcr-20-1718","volume":"9","author":"M Zhang","year":"2020","unstructured":"Zhang M, Xu F, Ni W, Qi W, Cao W, Xu C et al (2020) Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients. Transl Cancer Res 9:5450\u20135458","journal-title":"Transl Cancer Res"},{"key":"4545_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11060-019-03120-3","volume":"142","author":"A De Barros","year":"2019","unstructured":"De Barros A, Attal J, Roques M, Nicolau J, Sol J-C, Cohen-Jonathan-Moyal E et al (2019) Impact on survival of early tumor growth between surgery and radiotherapy in patients with de novo glioblastoma. J Neurooncol 142:489\u2013497","journal-title":"J Neurooncol"},{"key":"4545_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11060-017-2511-z","volume":"134","author":"JE Villanueva-Meyer","year":"2017","unstructured":"Villanueva-Meyer JE, Han SJ, Cha S, Butowski NA (2017) Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. J Neurooncol 134:213\u2013219","journal-title":"J Neurooncol"},{"key":"4545_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3171\/2014.9.JNS14193","volume":"122","author":"MZ Sun","year":"2015","unstructured":"Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET et al (2015) Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg 122:1144\u20131150","journal-title":"J Neurosurg"},{"key":"4545_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s12094-012-0916-x","volume":"15","author":"I Valduvieco","year":"2013","unstructured":"Valduvieco I, Verger E, Bruna J, Caral L, Pujol T, Ribalta T et al (2013) Impact of radiotherapy delay on survival in glioblastoma. Clin Transl Oncol 15:278\u2013282","journal-title":"Clin Transl Oncol"},{"key":"4545_CR12","volume":"14","author":"C Ekhator","year":"2022","unstructured":"Ekhator C, Nwankwo I, Rak E, Homayoonfar A, Fonkem E, Rak R (2022) GammaTile: comprehensive review of a novel radioactive intraoperative seed-loading device for the treatment of brain tumors. Cureus 14:e29970","journal-title":"Cureus"},{"key":"4545_CR13","first-page":"vdab185","volume":"4","author":"DJ Gessler","year":"2022","unstructured":"Gessler DJ, Neil EC, Shah R, Levine J, Shanks J, Wilke C et al (2022) GammaTile\u00ae brachytherapy in the treatment of recurrent glioblastomas. Neurooncol Adv 4:vdab185","journal-title":"Neurooncol Adv"},{"key":"4545_CR14","volume":"13","author":"HC Budnick","year":"2021","unstructured":"Budnick HC, Richardson AM, Shiue K, Watson G, Ng SK, Le Y et al (2021) GammaTile for gliomas: a single-center case series. Cureus 13:e19390","journal-title":"Cureus"},{"key":"4545_CR15","volume":"13","author":"S Mehta","year":"2021","unstructured":"Mehta S, Vassantachart AK, Fossum CC, Yang W, Shen ZL, Chang K-E et al (2021) Surviving over a decade with glioblastoma: a clinical course characterized by multiple recurrences, numerous salvage treatments, and novel use of cesium-131 tiles. Cureus 13:e19573","journal-title":"Cureus"},{"key":"4545_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100910","volume":"7","author":"GP Penoncello","year":"2022","unstructured":"Penoncello GP, Gagneur JD, Vora SA, Yu NY, Fatyga M, Mrugala MM et al (2022) Comprehensive commissioning and clinical implementation of GammaTiles STaRT for intracranial brain cancer. Adv Radiat Oncol 7:100910","journal-title":"Adv Radiat Oncol"},{"key":"4545_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.brachy.2021.08.011","volume":"20","author":"S McClelland","year":"2021","unstructured":"McClelland S, Gardner UG, Le Y, Ng SK, Shah MV, Watson GA (2021) Safety and efficacy of GammaTile intracranial brachytherapy implanted during awake craniotomy. Brachytherapy 20:1265\u20131268","journal-title":"Brachytherapy"},{"key":"4545_CR18","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.2217\/fon-2020-0558","volume":"16","author":"DJ Gessler","year":"2020","unstructured":"Gessler DJ, Ferreira C, Dusenbery K, Chen CC (2020) GammaTile: surgically targeted radiation therapy for glioblastomas. Future Oncol 16:2445\u20132455","journal-title":"Future Oncol"},{"key":"4545_CR19","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.brachy.2020.12.005","volume":"20","author":"C Ferreira","year":"2021","unstructured":"Ferreira C, Sterling D, Reynolds M, Dusenbery K, Chen C, Alaei P (2021) First clinical implementation of GammaTile permanent brain implants after FDA clearance. Brachytherapy 20:673\u2013685","journal-title":"Brachytherapy"},{"key":"4545_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.ijrobp.2007.03.061","volume":"69","author":"AM Chen","year":"2007","unstructured":"Chen AM, Chang S, Pouliot J, Sneed PK, Prados MD, Lamborn KR et al (2007) Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69:825\u2013830","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4545_CR21","volume":"13","author":"TP Easwaran","year":"2021","unstructured":"Easwaran TP, Sterling D, Ferreira C, Sloan L, Wilke C, Neil E et al (2021) Rapid interval recurrence of glioblastoma following gross total resection: a possible indication for GammaTile\u24c7 brachytherapy. Cureus 13:e19496","journal-title":"Cureus"},{"key":"4545_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3171\/2018.7.JNS18656","volume":"131","author":"DG Brachman","year":"2018","unstructured":"Brachman DG, Youssef E, Dardis CJ, Sanai N, Zabramski JM, Smith KA et al (2018) Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. J Neurosurg 131:1819\u20131828","journal-title":"J Neurosurg"},{"key":"4545_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459\u2013466","journal-title":"Lancet Oncol"},{"key":"4545_CR24","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3171\/jns.2003.98.6.1175","volume":"98","author":"SM Chang","year":"2003","unstructured":"Chang SM, Parney IF, McDermott M, Barker FG 2nd, Schmidt MH, Huang W et al (2003) Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the glioma outcome project. J Neurosurg 98:1175\u20131181","journal-title":"J Neurosurg"},{"key":"4545_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/0976-3147.91927","volume":"3","author":"AV Moiyadi","year":"2012","unstructured":"Moiyadi AV, Shetty PM (2012) Perioperative outcomes following surgery for brain tumors: objective assessment and risk factor evaluation. J Neurosci Rural Pract 3:28\u201335","journal-title":"J Neurosci Rural Pract"},{"key":"4545_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1227\/neu.0000000000002063","volume":"91","author":"D Botros","year":"2022","unstructured":"Botros D, Khalafallah AM, Huq S, Dux H, Oliveira LAP, Pellegrino R et al (2022) Predictors and impact of postoperative 30-day readmission in glioblastoma. Neurosurgery 91:477\u2013484","journal-title":"Neurosurgery"},{"key":"4545_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153907","author":"J Kasper","year":"2023","unstructured":"Kasper J, Wach J, Vychopen M, Arlt F, G\u00fcresir E, Wende T et al (2023) Unplanned 30-day Readmission in glioblastoma patients: implications for the extent of resection and adjuvant therapy. Cancers. https:\/\/doi.org\/10.3390\/cancers15153907","journal-title":"Cancers"},{"key":"4545_CR28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3109\/02688697.2013.791664","volume":"27","author":"A Gutenberg","year":"2013","unstructured":"Gutenberg A, Bock HC, Br\u00fcck W, Doerner L, Mehdorn HM, Roggendorf W et al (2013) MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Br J Neurosurg 27:772\u2013778","journal-title":"Br J Neurosurg"},{"key":"4545_CR29","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1002\/cncr.24546","volume":"115","author":"P Metellus","year":"2009","unstructured":"Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R et al (2009) Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer 115:4783\u20134794","journal-title":"Cancer"},{"key":"4545_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/neurosurgery\/23.CN_suppl_1.32","volume":"23","author":"W Sweet","year":"1976","unstructured":"Sweet W (1976) The difference between zero and one. Clin Neurosurg 23:32\u201351","journal-title":"Clin Neurosurg"},{"key":"4545_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/02688697.2021.1907306","volume":"35","author":"C Luo","year":"2021","unstructured":"Luo C, Song K, Wu S, Hameed NUF, Kudulaiti N, Xu H et al (2021) The prognosis of glioblastoma: a large, multifactorial study. Br J Neurosurg 35:555\u2013561","journal-title":"Br J Neurosurg"},{"key":"4545_CR32","doi-asserted-by":"publisher","first-page":"e847","DOI":"10.1016\/j.wneu.2022.11.143","volume":"170","author":"A Pando","year":"2023","unstructured":"Pando A, Patel AM, Choudhry HS, Eloy JA, Goldstein IM, Liu JK (2023) Palliative care effects on survival in glioblastoma: who receives palliative care? World Neurosurg 170:e847\u2013e857","journal-title":"World Neurosurg"},{"key":"4545_CR33","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1093\/neuonc\/noac133","volume":"24","author":"K Smith","year":"2022","unstructured":"Smith K, Nakaji P, Thomas T, Pinnaduwage D, Wallstrom G, Choi M et al (2022) Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: results from a prospective trial. Neuro Oncol 24:S4\u2013S15","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04545-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-023-04545-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-023-04545-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T07:49:42Z","timestamp":1708588182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-023-04545-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4545"],"URL":"https:\/\/doi.org\/10.1007\/s11060-023-04545-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"16 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CF: received grant support from GT Medical. CCC: is a primary investigator for the studies sponsored by GT Medical. In accordance with University of Minnesota COI policy, the senior author cannot and do not receive stipend or any payment from GT Medical. The senior author does receive reimbursement for travel expenses related to the presentation of clinical experiences related to the clinical application of GammaTiles. No additional payment is received from GT Medical beyond such reimbursements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}